Featured

BBVA Compass Bank supports science education at HudsonAlpha


HudsonAlpha's educational outreach team received a big boost from BBVA Compass Bank when the local financial institution donated almost $6,000 toward the Science for Me Too! program. 
 
This program creates opportunities for underserved students to experience science and lab activities outside of the regular school day. Through the generous support of BBVA Compass Bank, more than 489 elementary and middle school students have participated in hands-on science activities. Activities have taken place at the institute, as well as Sci-Quest Hands-on Science Center.
 

International team works toward sustainable peach

HUNTSVILLE, Ala. -- Advancing work toward sustainable crops and sustainable fuels is among potential outcomes from a project undertaken by the International Peach Genome Initiative. The initiative, including researchers at the HudsonAlpha Institute for Biotechnology and the Department of Energy Joint Genome Institute, has completed the draft genome of peach, Prunus persica, and published findings in the March 24 edition of Nature Genetics.

EGEN announces phase I clinical trial for advanced ovarian cancer

News Outlet: 
PR Newswire
Date published: 
March 19, 2013

HUNTSVILLE, Ala. -- EGEN, Inc. today announced that it has recently initiated a Phase I clinical trial of its novel immunotherapy agent, EGEN-001, in combination with PEGylated liposomal Doxorubicin or Lipodox for the treatment of recurrent ovarian cancer. The EGEN-sponsored trial is conducted by a network of researchers led by Gynecologic Oncology Group (GOG) at member institutions under an agreement between the GOG and EGEN, Inc. Premal Thaker, M.D., M.S., of Washington University School of Medicine, is the Study Chair for the trial.

Retired Lt. Gen. Joseph M. Cosumano named incoming CFDRC president


Huntsville, Ala. – Joseph M. Cosumano joins CFD Research Corporation (CFDRC) as president, effective Feb. 1, 2013. Cosumano’s military and civilian experience in key modernization efforts make him a perfect fit to lead CFDRC as it continues to make significant discoveries and applications. 
 

Serina Therapeutics announces agreement with AstraZeneca for development of polymer


Serina Therapeutics, Inc. has developed a proprietary, patented polymer technology for drug development and announced an agreement with AstraZeneca to develop the polyoxazoline (POZ) polymer therapeutic with an AstraZeneca proprietary compound. The nature of the POZ therapeutic and the terms of the agreement were not immediately disclosed. 

Jeremy Schmutz receives cotton biotechnology award

News Outlet: 
PR Newswire
Date published: 
January 16, 2013

NEW YORK, Jan. 17, 2013 -- As part of the recent Plant and Animal Genomic Conference held in San Diego, Calif., Dr. Don Jones of Cotton Incorporated presented the 2012 Cotton Biotechnology Award to five outstanding researchers that were instrumental in mapping the cotton genome. The diverse and talented team, composed of Dr. Andrew Paterson, Dr. Jonathan Wendel, Mr. Jeremy Schmutz, Dr. Dan Peterson and Dr. Dan Rokhsar, led the collaborative international effort to complete the first "gold standard" Gossypium genome sequence.  

HudsonAlpha partners with city in Healthy Huntsville 2013 campaign

News Outlet: 
The Huntsville Times
Date published: 
January 15, 2013

HUNTSVILLE, Alabama - The Rocket City's battle against bulge is getting serious. On Tuesday, Mayor Tommy Battle announced an expanded Healthy Huntsville campaign designed to help folks slim down and live longer. The city is working with Huntsville Hospital, city schools, the county health department and HudsonAlpha Institute for Biotechnology to offer at least one free, fitness-related event per week in 2013.

Luncheon supports HudsonAlpha research

For a second year, Huntsville philanthropists Pennie and Tom Keene hosted a women's luncheon in support of HudsonAlpha. Donations from luncheon guests, which were supplemented by the Keenes and a matching gift from UBS Financial Services, will support research projects at HudsonAlpha.

Reuters highlights CFDRC in vitro tumor model

News Outlet: 
Reuters
Date published: 
December 11, 2012

 

CFD Research Corporation has been awarded a $1.3 million grant from the National Institutes of Health to develop their novel in vitro tumor model. SynVivo-Tumor replicates the tumor microenvironment with physiologically and morphologically realistic microvasculature including endothelial cell-lined leaky vessels and 3D solid tumors. Tumor drug delivery is a complex phenomenon affected by several elements in addition to physico-chemical properties. 
 
"Current in vitro models of tumor drug delivery are oversimplified and show poor correlation with in vivo performance," said Prabhakar Pandian, Ph.D., CFDRC principal investigator. "Our novel platform mimics the in vivo environment with physiologically relevant flow resulting in endothelial cell lined capillary vessels and 3D solid tumors. Most importantly, the SynVivo-Tumor platform enables real-time, quantitative assessment of the performance of drug delivery vehicles."

Popular Science lists IDair's fingerprint scanner in its "best of" list

News Outlet: 
Popular Science/The Huntsville Times
Date published: 
November 27, 2012

 

Huntsville, Ala. - A Huntsville company whose fingerprint scanner can photographically capture fingerprints from as far as six meters has been named to Popular Science's "Best of What's New" list.
 
The product, AIRprint, is made by IDair, a HudsonAlpha-based spinoff of Advanced Optical Systems. Most of IDair's customers are military, but this summer, a 24-hour fitness center was beta-testing the system as a way to stop people from sharing access keys without paying. The product, according to Popular Science, costs $5,000.
 
Click here to see the follow-up story on this HudsonAlpha resident associate company in the Huntsville Times. To see the product in Popular Science, click here
Syndicate content